Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of the drugs
OSI-774 and docetaxel that can be given together along with radiation treatment for advanced
head and neck cancer.